124 related articles for article (PubMed ID: 37431107)
21. Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer.
Falk GW; Thota PN; Richter JE; Connor JT; Wachsberger DM
Clin Gastroenterol Hepatol; 2005 Nov; 3(11):1089-94. PubMed ID: 16271339
[TBL] [Abstract][Full Text] [Related]
22. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
23. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
[TBL] [Abstract][Full Text] [Related]
24. Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network.
O'Byrne LM; Witherspoon J; Verhage RJJ; O'Brien M; Muldoon C; Ryan C; Buckley M; Murphy T; Reynolds R; Patchett S; Kay E; Azam H; Robb W; Arumugasamy M; Mathuna PM; Leyden J; Gargan S; Doherty G; Sheahan K; Collins C; Nath A; O'Sullivan J; Donohoe CL; Ravi N; O'Toole D; Reynolds JV
Dis Esophagus; 2020 Oct; 33(10):. PubMed ID: 32193532
[TBL] [Abstract][Full Text] [Related]
25. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
[TBL] [Abstract][Full Text] [Related]
26. Marital status and quality of life in patients with esophageal cancer or Barrett's esophagus: the mayo clinic esophageal adenocarcinoma and Barrett's esophagus registry study.
Miller RC; Atherton PJ; Kabat BF; Fredericksen MB; Geno DM; Deschamps C; Jatoi A; Sloan JA; Romero Y
Dig Dis Sci; 2010 Oct; 55(10):2860-8. PubMed ID: 20094784
[TBL] [Abstract][Full Text] [Related]
27. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
[TBL] [Abstract][Full Text] [Related]
28. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
29. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
30. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.
Krishnamoorthi R; Borah B; Heien H; Das A; Chak A; Iyer PG
Gastrointest Endosc; 2016 Jul; 84(1):40-46.e7. PubMed ID: 26772891
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
[TBL] [Abstract][Full Text] [Related]
32. A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia.
Picardo SL; O'Brien MP; Feighery R; O'Toole D; Ravi N; O'Farrell NJ; O'Sullivan JN; Reynolds JV
Dis Esophagus; 2015; 28(2):121-6. PubMed ID: 24428806
[TBL] [Abstract][Full Text] [Related]
33. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
34. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of Barrett's high-grade dysplasia.
Weston AP; Sharma P; Topalovski M; Richards R; Cherian R; Dixon A
Am J Gastroenterol; 2000 Aug; 95(8):1888-93. PubMed ID: 10950031
[TBL] [Abstract][Full Text] [Related]
36. Presence or absence of intestinal metaplasia but not its burden is associated with prevalent high-grade dysplasia and cancer in Barrett's esophagus.
Bansal A; McGregor DH; Anand O; Singh M; Rao D; Cherian R; Wani SB; Rastogi A; Singh V; House J; Jones PG; Sharma P
Dis Esophagus; 2014; 27(8):751-6. PubMed ID: 24165297
[TBL] [Abstract][Full Text] [Related]
37. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
[TBL] [Abstract][Full Text] [Related]
38. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
[TBL] [Abstract][Full Text] [Related]
39. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
40. The Troublesome Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.
Schneider JL; Corley DA
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):353-364. PubMed ID: 28577761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]